Anti-AIDS agents. 37. Synthesis and structure-activity relationships of (3'R,4'R)-(+)-cis-khellactone derivatives as novel potent anti-HIV agents

Journal of Medicinal Chemistry

Volumn 42, Issue 14, 1999, Pages 2662-2672

  Xie, Lan ^a   Takeuchi, Yasuo ^a   Cosentino, L Mark ^b   Lee, Kuo Hsiung ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b BBI Biotech Research Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3',4' DI O CAMPHANOYL 3 METHYL KHELLACTONE; 3',4' DI O CAMPHANOYL 4 METHYL KHELLACTONE; 3',4' DI O CAMPHANOYL 5 METHYL KHELLACTONE; 3',4' DI O CAMPHANOYL KHELLACTONE; ANTIRETROVIRUS AGENT; KHELLACTONE; PHYTOHEMAGGLUTININ; UNCLASSIFIED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE; VIRUS REPLICATION;

ANTI-HIV AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; CELL LINE; COUMARINS; DRUG DESIGN; HIV-1; HUMANS; LYMPHOCYTES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

EID: 0033566219     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9900624     Document Type: Article

References (38)

1. Xia, P.; Yang, Z.; Xia, Y.; Zheng, Y.; Cosentino, L. M.; Lee, K. H. Anti-HIV agents 36. 17-Carboxylated steroids as potential anti-HIV agents. Bioorg. Med. Chem. Submitted.
2. Gallo, R. C.; Sarin, P. S.; Gelmann, E. P.; Robert-Guroff, M.; Richardson, E.; Kalyanaraman, V. S.; Mann, D.; Sidhu, G. D.; Stahl, R. E.; Zolla-Prazner, S.; Leibowitch, J.; Popovic, M. Isolation of a T-cell leukemia virus in acquired immunodeficiency syndrome (AIDS). Science 1983, 220, 865-867.
3. Barre-Sinoussi, F.; Chermann, J. C.; Rey, F.; Nugeyre, M. T.; Chamaret, S.; Gruest, J.; Dauguet, C.; Axler-Blin, C.; Vezinet-Brun, F.; Rouzioux, C.; Rozenbaum, W.; Montagnier, L. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983, 220, 868-871.
4. De Clercq, E. Toward improved anti-HIV chemotherapy: Therapeutic strategies for intervention with HIV infections. J. Med. Chem. 1995, 38, 2491-2517.
5. Dormont, J. Future treatment strategies in HIV-infection. AIDS 1994, 8 (Suppl. 3), S31-S33.
6. Sarin, P. S.; Goldstein, A. L. Treatment of AIDS with drugs targeted to inhibit different stages of the HIV life cycle. Immunopharmacol. Immunotoxicol. 1995, 17, 217-245.
7. Reported by Office of Special Health Issues, Food and Drug Administration. December 22, 1998.
8. Schmit, J. C.; Ruiz, L.; Clotet, B.; Raventos, A.; Tor, J.; Leonard, J.; Desmyter, J.; De Clercq, E.; Vandamme, A. M. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS 1996, 10, 995-999.
9. Gu, Z. X.; Fletcher, R. S.; Arts, E. J.; Wainberg, M. A.; Parniak, M. A. The K65R mutant reverse-transcriptase of HIV-1 cross-resistant to 2′,3′-dideoxycytidine, 2′,3′-dideoxy-3′-thiacytidine, and 2′,3′-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro. J. Biol. Chem. 1994, 269, 28118-28122.
10. Najera, I.; Richman, D. D.; Olivares, I.; Rojas, J. M.; Peinado, M. A.; Perucho, M.; Najera, R.; Lopez-Galindez, C. Natural occurrence of drug-resistance mutations in the reverse-transcriptase of human-immunodeficiency-virus type-1 isolates. AIDS Res. Hum. Retroviruses 1994, 10, 1479-1488.
11. Stclair, M. H.; Martin, J. L.; Tudor-Williams, G.; Bach, M. C.; Vavro, C. L.; King, D. M.; Kellam, P.; Kemp, S. D.; Larder, B. A. Resistance to DDI and sensitivity to AZT induced by a mutation in HIV-1 reverse-transcriptase. Science 1991, 253, 1557-1559.
12. Elfarrash, M. A.; Kuroda, M. J.; Kitazaki, T.; Masuda, T.; Kato, K.; Hatanaka, M.; Harada, S. Generation and characterization of a human-immunodeficiency-virus type-1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor. J. Virol. 1994, 68, 233-239.
13. Borman, A. M.; Paulous, S.; Clavel, F. Resistance of human immunodeficiency virus type 1 to protease inhibitors: Selection of resistance mutations in the presence and absence of the drug. J. Gen. Virol. 1996, 77, 419-426.
14. Lee, T. T.-Y.; Kashiwada, Y.; Huang, L.; Snider, J.; Cosentino, L. M.; Lee, K. H. Suksdorfin: An anti-HIV principle from Lomatium suksdorfii, its structure-activity correlation with related coumarins, and synergistic effects with anti-AIDS nucleosides. Bioorg. Med. Chem. 1994, 2, 1051-1056.
15. Pettinato, F. A.; Fischer, L.; Hall, N. A. A note on the preliminary phytochemical and biological study of Lomatium suksdorfii. J. Am. Pharm. Assoc. 1959, 48, 423-423.
16. Willette, R. E.; Soine, T. O. Isolation, purification, and structure determination of pteryxin and suksdorfin. J. Pharm. Sci. 1962, 51, 149-156.
17. Kemmich, J.; Pederson, P. A.; Nielsen, B. E. Revised absolute configuration of natural khellactone esters (1). Tetrahedron Lett. 1969, 3365-3366.
18. Huang, L.; Kashiwada, Y.; Cosentino, L. M.; Fan, S.; Chen, C. H.; McPhail, A. T.; Fujioka, T.; Mihashi, K.; Lee, K. H. Anti-AIDS agents 15. Synthesis and anti-HIV activity of dihydroseselins and related analogues. J. Med. Chem. 1994, 37, 3947-3955.
19. Huang, L.; Kashiwada, Y.; Cosentino, L. M.; Fan, S.; Lee, K. H. Anti-AIDS agents 14. 3′,4′-Di-O-(-)-camphanoyl-(+)-cis-khel-lactone and related compounds: A new class of potent anti-HIV agents. Bioorg. Med. Chem. 1994, 4, 593-598.
20. Takeuchi, Y.; Xie, L.; Cosentino, L. M.; Lee K. H. Anti-AIDS agents 28. Synthesis and anti-HIV activity of methoxy substituted 3′,4′-di-O-(-)-camphanoyl-(+)-cis-khellactone (DCK) analogues. Bioorg. Med. Chem. Lett. 1997, 7, 2573-2578.
21. Xie, L.; Takeuchi, Y.; Cosentino, L. M.; Lee K. H. Anti-AIDS agents 33. Synthesis and anti-HIV activity of monomethyl substituted 3′,4′-di-O-(-)-camphanoyl-(+)-cis-khellactone (DCK) analogues. Bioorg. Med. Chem. Lett. 1998, 8, 2151-2156.
22. Pandey, G.; Muralikrishna, C.; Bhalerao, U. T. Mushroom tyrosinase catalyzed synthesis of coumestans, benzofuran derivatives and related heterocyclic compounds. Tetrahedron 1989, 45, 6867-6874.
23. Ahlumalia, Y. K.; Kumar, D. Partial methylation of 4-hydroxyl group in coumarins. Indian J. Chem. 1977, 15B, 945-946.
24. Harayama, T.; Katsuno, K.; Nishioka, H.; Fujii, M.; Nishita, Y.; Ishii, H.; Kaneko, Y. A convenient synthesis of a simple coumarin from salicylaldehyde and Wittig reagent (I). A synthesis of methoxycoumarin and hydroxycoumarin. Heterocydes 1994, 39, 613-622.
25. Harayama, T.; Nakatsuka, K.; Nishioka, H.; Murakami, K.; Ohmori, Y.; Takeuchi, Y.; Ishii, H.; Kenmotsu, K. Convenient synthesis of a simple coumarin from salocyaldehyde and Wittig reagent (III). Synthesis of nitrocoumarins. Heterocycles 1994, 38, 2729-2738.
26. Smith, G. F. Indoles. Part I. The formylation of indole and some reactions of 3-formylindole. J. Chem. Soc. 1954, 3842-3846.
27. Ishii, H.; Ishikawa, T.; Wada, H.; Miyazaki, H.; Kaneko, Y.; Harayama, T. Synthetic studies on naturally occurring coumarins. II. Synthesis of 6,7-dimethoxy-and 7,8-dimethoxy-5-[(E)-3-oxo-1-butenyl]coumarins. Chem. Pharm. Bull. 1992, 40, 2614-2619.
28. Elliger, C. A. Deoxygenation of aldehydes and ketones with sodium cyanoborohydride. Synth. Commun. 1985, 15, 1315-1324.
29. Fall, Y.; Santana, L.; Teijeira, M.; Uriarte, E. A convenient synthesis of benzofuran-3-acetic acids. Heterocycles 1995, 41, 647-650.
30. Hlubucek, J.; Ritchie, E.; Taylor, W. C. Synthesis of 2,2-dimethylchromenes. Aust. J. Chem. 1971, 24, 2347-2354.
31. Murray, R. D. H.; Ballantyne, M. M.; Mathai, K. P. Claisen rearrangements III. Convenient synthesis of the coumarins, osthenol, demethylsuberosin and coumurrayin. Tetrahedron 1971, 27, 1247-1251.
32. Xie, L.; Crimmins, M. T.; Lee, K. H. Asymmetric synthesis of 3′,4′-di-O-(-)-camphanoyl-(+)-cis-khellactone (DCK), a potent anti-HIV agent. Tetrahedron Lett. 1995, 36, 4529-4532.
33. Crispino, G. A.; Jeong, K. S.; Kolb, H. C.; Wang, Z. M.; Xu, D. Q.; Sharpless, K. B. Improved enantioselectivity in asymmetric dihydroxylations of terminal olefins using pyrimidine ligands. J. Org. Chem. 1993, 58, 3785-3786.
34. Wang, L.; Sharpless, K B. Catalytic asymmetric dihydroxylation of cis-disubstituted olefins. J. Am. Chem. Soc. 1992, 114, 7568-7570.
35. Norrby, P. O.; Becker, H.; Sharpless, K. B. Toward an understanding of the high enantioselectivity in the osmium-catalyzed asymmetric dihydroxylation 3. New insights into isomeric forms of the putative osmaoxetane intermediate. J. Am. Chem. Soc. 1996, 118, 35-42.
36. Norrby, P. O.; Kolb, H. C.; Sharpless, K. B. Asymmetric dihydroxylation 2. A qualitative molecular mechanics approach. J. Am. Chem. Soc. 1994, 116, 8470-8478.
37. This assay was performed by the National Cancer Institute, Bethesda, Maryland.
38. Weislow, O. W.; Kiser, R.; Fine, D.; Bader, J.; Shoemaker, R. H.; Boyd, M. R. New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J. Natl. Cancer Inst. 1989, 81, 577-586.